EirGenix Signs Exclusive License Agreement for Biosimilar EG1206A with Sandoz EirGenix has secured a global exclusive license deal with Sandoz for its HER2 biosimilar EG1206A, marking a significant milestone in oncology.

EirGenix Signs Exclusive License Agreement for Biosimilar EG1206A with Sandoz #Taiwan #Taipei #Sandoz #EirGenix #EG1206A

EirGenix Strengthens Global Presence with New Biosimilar HER2 Licensing Agreement EirGenix secures a global exclusive licensing agreement for biosimilar EG1206A, enhancing cancer treatment options and market presence.

EirGenix Strengthens Global Presence with New Biosimilar HER2 Licensing Agreement #Taiwan #Taipei #HER2 #EirGenix #EG1206A

EirGenix Strengthens Biosimilar Portfolio with New Licensing Agreement for EG1206A EirGenix Inc. has announced a global licensing agreement with Sandoz for its HER2 biosimilar EG1206A, enhancing cancer treatment options and supporting global access.

EirGenix Strengthens Biosimilar Portfolio with New Licensing Agreement for EG1206A #Taiwan #Taipei #Sandoz #EirGenix #EG1206A

EirGenix Secures Second Global Licensing Deal for HER2 Biosimilar EG1206A EirGenix Inc. has announced a significant global licensing agreement with Sandoz for its HER2 biosimilar EG1206A, enhancing treatment for breast cancer patients.

EirGenix Secures Second Global Licensing Deal for HER2 Biosimilar EG1206A #Taiwan #Taipei #Sandoz #EirGenix #EG1206A